{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:11:47Z","timestamp":1785471107578,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,7]]},"DOI":"10.7759\/cureus.104843","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T07:38:36Z","timestamp":1772955516000},"source":"Crossref","is-referenced-by-count":1,"title":["Effective Management of Chemotherapy-Induced Cardiotoxicity: A Prospective Follow-Up Study on Alternative Regimens in Bangladeshi Cancer Patients"],"prefix":"10.7759","author":[{"given":"Md. Zillur Rahman","family":"Bhuiyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harisul","family":"Hoque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarwar","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.88372","article-title":"Cardiac complications in cancer patients following chemotherapy and radiotherapy","volume":"17","author":"Bhuiyan MZ","year":"2025","unstructured":"Bhuiyan MZ, Hoque H, Alam S. Cardiac complications in cancer patients following chemotherapy and radiotherapy. Cureus. 2025, 17:e88372. 10.7759\/cureus.88372","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano JL","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, et al.. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016, 37:2768-801. 10.1093\/eurheartj\/ehw211","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000556","article-title":"Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association","volume":"137","author":"Mehta LS","year":"2018","unstructured":"Mehta LS, Watson KE, Barac A, et al.. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018, 137:e30-66. 10.1161\/CIR.0000000000000556","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi JJ","year":"2016","unstructured":"Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016, 375:1457-67. 10.1056\/NEJMra1100265","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/2050-6511-15-47","article-title":"A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity","volume":"15","author":"Polk A","year":"2014","unstructured":"Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014, 15:47. 10.1186\/2050-6511-15-47","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\u2122\/Doxil\u00ae) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien ME","year":"2004","unstructured":"O'Brien ME, Wigler N, Inbar M, et al.. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\u2122\/Doxil\u00ae) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer. Ann Oncol. 2004, 15:440-9. 10.1093\/annonc\/mdh097","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.05.005","article-title":"Lung cancer in Bangladesh","volume":"18","author":"Islam MR","year":"2023","unstructured":"Islam MR, Siddiqua SM, Islam R, et al.. Lung cancer in Bangladesh. J Thorac Oncol. 2023, 18:972-80. 10.1016\/j.jtho.2023.05.005","journal-title":"J Thorac Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global Cancer Statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global Cancer Statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4954095","article-title":"Universal health coverage in Bangladesh: activities, challenges, and suggestions","volume":"2019","author":"Joarder T","year":"2019","unstructured":"Joarder T, Chaudhury TZ, Mannan I. Universal health coverage in Bangladesh: activities, challenges, and suggestions. Psyche (Camb Mass). 2019, 2019:4954095. 10.1155\/2019\/4954095","journal-title":"Psyche (Camb Mass)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist G","year":"2001","unstructured":"Batist G, Ramakrishnan G, Rao CS, et al.. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001, 19:1444-54. 10.1200\/JCO.2001.19.5.1444","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(01)00050-8","article-title":"Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\u00ae\/CAELYX\u00ae) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group","volume":"37","author":"Judson I","year":"2001","unstructured":"Judson I, Radford JA, Harris M, et al.. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\u00ae\/CAELYX\u00ae) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001, 37:870-7. 10.1016\/s0959-8049(01)00050-8","journal-title":"Eur J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003663","article-title":"Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan","volume":"3","author":"Shaikh AS","year":"2013","unstructured":"Shaikh AS, Saleem AF, Mohsin SS, Alam MM, Ahmed MA. Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan. BMJ Open. 2013, 3:e003663. 10.1136\/bmjopen-2013-003663","journal-title":"BMJ Open"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00396","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 phase III study","volume":"39","author":"Hong S","year":"2021","unstructured":"Hong S, Zhang Y, Yu G, et al.. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 phase III study. J Clin Oncol. 2021, 39:3273-82. 10.1200\/JCO.21.00396","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)","volume":"43","author":"Lyon AR","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al.. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022, 43:4229-361. 10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0053","article-title":"NCCN guidelines\u00ae insights: breast cancer, version 5.2025","volume":"23","author":"Gradishar WJ","year":"2025","unstructured":"Gradishar WJ, Moran MS, Abraham J, et al.. NCCN guidelines\u00ae insights: breast cancer, version 5.2025. J Natl Compr Canc Netw. 2025, 23:426-36. 10.6004\/jnccn.2025.0053","journal-title":"J Natl Compr Canc Netw"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer EA","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45:228-47. 10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-SREV","article-title":"Summary of revisions: standards of care in diabetes-2025","volume":"48","year":"2025","unstructured":"Summary of revisions. standards of care in diabetes-2025. Diabetes Care. 2025, 48:S6-S13. 10.2337\/dc25-SREV","journal-title":"Diabetes Care"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez A","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021, 112:90-2. 10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.121.316697","article-title":"Cardiotoxicity of cancer treatments: focus on anthracycline cardiomyopathy","volume":"41","author":"Nishi M","year":"2021","unstructured":"Nishi M, Wang PY, Hwang PM. Cardiotoxicity of cancer treatments: focus on anthracycline cardiomyopathy. Arterioscler Thromb Vasc Biol. 2021, 41:2648-60. 10.1161\/ATVBAHA.121.316697","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.14797\/mdcj-15-4-243","article-title":"Heart failure in relation to anthracyclines and other chemotherapies","volume":"15","author":"Agunbiade TA","year":"2019","unstructured":"Agunbiade TA, Zaghlol RY, Barac A. Heart failure in relation to anthracyclines and other chemotherapies. Methodist Debakey Cardiovasc J. 2019, 15:243-9. 10.14797\/mdcj-15-4-243","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon A","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003, 42:419-36. 10.2165\/00003088-200342050-00002","journal-title":"Clin Pharmacokinet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2081","article-title":"Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial","volume":"17","author":"Crin\u00f2 L","year":"1999","unstructured":"Crin\u00f2 L, Mosconi AM, Scagliotti G, et al.. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol. 1999, 17:2081-5. 10.1200\/JCO.1999.17.7.2081","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management","volume":"109","author":"Yeh ET","year":"2004","unstructured":"Yeh ET, Tong AT, Lenihan DJ, et al.. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004, 109:3122-31. 10.1161\/01.CIR.0000133187.74800.B9","journal-title":"Circulation"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby SC","year":"2013","unstructured":"Darby SC, Ewertz M, McGale P, et al.. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013, 368:987-98. 10.1056\/NEJMoa1209825","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf275","article-title":"A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK","volume":"13","author":"Smith DH","year":"2002","unstructured":"Smith DH, Adams JR, Johnston SR, Gordon A, Drummond MF, Bennett CL. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann Oncol. 2002, 13:1590-7. 10.1093\/annonc\/mdf275","journal-title":"Ann Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.4091","article-title":"Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31","volume":"23","author":"Tan-Chiu E","year":"2005","unstructured":"Tan-Chiu E, Yothers G, Romond E, et al.. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005, 23:7811-9. 10.1200\/JCO.2005.02.4091","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt140","article-title":"Cancer control in Bangladesh","volume":"43","author":"Hussain SA","year":"2013","unstructured":"Hussain SA, Sullivan R. Cancer control in Bangladesh. Jpn J Clin Oncol. 2013, 43:1159-69. 10.1093\/jjco\/hyt140","journal-title":"Jpn J Clin Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.09.006","article-title":"Genetics of anthracycline cardiomyopathy in cancer survivors: JACC: CardioOncology state-of-the-art review","volume":"2","author":"Bhatia S","year":"2020","unstructured":"Bhatia S. Genetics of anthracycline cardiomyopathy in cancer survivors: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2020, 2:539-52. 10.1016\/j.jaccao.2020.09.006","journal-title":"JACC CardioOncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm E","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007, 4:e296. 10.1371\/journal.pmed.0040296","journal-title":"PLoS Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/455936-effective-management-of-chemotherapy-induced-cardiotoxicity-a-prospective-follow-up-study-on-alternative-regimens-in-bangladeshi-cancer-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T07:38:37Z","timestamp":1772955517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/455936-effective-management-of-chemotherapy-induced-cardiotoxicity-a-prospective-follow-up-study-on-alternative-regimens-in-bangladeshi-cancer-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.104843","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,7]]}}}